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Accurate massively parallel sequencing (MPS) of genetic variants is key to many areas of science and medicine, such as cat-
aloging population genetic variation and diagnosing genetic diseases. Certain genomic positions can be prone to higher rates
of systematic sequencing and alignment bias that limit accuracy, resulting in false positive variant calls. Current standardprac-
tices to differentiate between loci that can and cannot be sequenced with high confidence utilize consensus between different
sequencingmethods as a proxy for sequencing confidence. These practices have significant limitations, and alternativemeth-
ods are required to overcome them. We have developed a novel statistical method based on summarizing sequenced reads
fromwhole-genome clinical samples and cataloging them in “Incremental Databases” thatmaintain individual confidentiality.
Allele statistics were cataloged for each genomic position that consistently showed systematic biases with the corresponding
MPS sequencing pipeline. We found systematic biases present at ∼1%–3% of the human autosomal genome across five pa-
tient cohorts. We identified which genomic regions were more or less prone to systematic biases, including large homopol-
ymer flanks (odds ratio = 23.29–33.69) and the NIST high confidence genomic regions (odds ratio =0.154–0.191). We
confirmed our predictions on a gold-standard reference genome and showed that these systematic biases can lead to suspect
variant calls within clinical panels. Our results recommend increased caution to address systematic biases in whole-genome
sequencing and alignment. This studyprovides the implementation of a simple statistical approach to enhance quality control
of clinically sequenced samples by flagging variants at suspect loci for further analysis or exclusion.
[Supplemental material is available for this article.]
DNA sequencing is an imperfect process and although error rates
are low, mistakes in identifying genomic variants can still occur.
While the sources of random sequencing errors are relatively well
understood (Benjamini and Speed 2012; Ma et al. 2019), identify-
ing systematic errors in whole genomes sequenced in a clinical or
commercial setting is not always possible due to restrictions in
gathering information about the samples and sequencing pro-
cesses. These errors could cause incorrect decisions on the pres-
ence or absence of disease-relevant variants in the genome and
influence clinical and research decisions (Goldfeder et al. 2016).
One of themajor challenges to improving variant detection is
that certain regions of the genome are prone to higher rates of sys-
tematic sequencing or alignment errors, which can result in the
false identification of variants at a low allelic fraction. In the case
of diploid genotype calls, variants are expected to be around a
50% or 100% allelic fraction, corresponding to heterozygous and
homozygous loci. However, real variants sometimes occur at low
allelic fractions, such as somatic variants in tumors and in cases
of mosaicism, where nearby cells sampled together can show ge-
netic heterogeneity within the sample (Vattathil and Scheet
2016; King et al. 2017). In these cases, the ability to identify loci
that systematically exhibit a low allelic fraction across individuals
becomes critical, since these artifacts may be misidentified as var-
iant alleles.
Lists of ‘high confidence’ loci from gold-standard reference
genomes are sometimes used for quality control purposes in clin-
ical and commercial sequencing laboratories, since they leave
out regions which cannot be sequenced reliably by any technolo-
gy, although they arenot designed to reflect high sequencing accu-
racy. For example, The National Institute of Standards and
Technology Genome in a Bottle Consortium (NIST GIAB) has pro-
posed a list of ‘high confidence’ genomic regions to be used for
benchmarking different sequencing methods, developed using a
top-down approach, by analyzing the consensus between different
sequencing technologies and variant callers for the same genomic
samples to develop a ‘truth set’ of variant calls (Zook et al. 2014,
2019). However, because genomic regions only require at least
one sequencing method showing no evidence of systematic error
to be included in the ‘high confidence’ list, the sequencing pipe-
line being used by any one scientist could be a different method
that is affected by systematic error, so filtering out genomic regions
not in the ‘high confidence’ list does not guarantee high sequenc-
ing accuracy in all remaining regions. This disparity between the
‘high confidence’ set and regions with high sequencing accuracy
for any one sequencing pipeline is likely to increase over time as
more genomic regions are included in the ‘high confidence’ set
which can be sequenced by long- and linked-read-based methods
but which show systematic biases with short-read-based
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sequencing. Another drawback is that clinically collected sam-
ples can vary in quality, and contamination may introduce vari-
ants with low allelic fractions not seen in reference genomes.
Furthermore, the number of reference genomes used may be quite
small, so sample-specific structural variants, which are not repre-
sentative of the diversity of clinically sequenced genomes, can
cause genomic regions to be missing from the ‘high confidence’
list despite having accurate sequencing for most samples.
Other top-down approaches of evaluating thresholds for alle-
lic fraction or read quality may differ depending on the variant
calling pipelines used (Sandmann et al. 2017). Benchmarking
these different approaches on cohorts of genomes may be insight-
ful for research but impractical for clinical applications, and it risks
leaking sensitive genetic information. Furthermore, standard qual-
ity control measures for variant calling can often be overly simplis-
tic, such as fixed read depth thresholds for calling variants across
the genome, which are not tailored to wide regional differences
in systematic biases. A reliance on high read depth for accurate var-
iant calling increases the costs of sequencing studies, which are
forced to compromise between the number of genomes sequenced
and the depth of coverage achieved (The 1000 Genomes Project
Consortium 2010).
A ‘bottom-up’ approach to learning about sequencing
error looks at different cohorts of clinically sequenced genomes in-
dependently and does not rely on consensus between multiple se-
quencing technologies. This study aims to address the limitations
affecting other quality control methods described above, by devel-
oping a ‘bottom-up’ method to evaluate position-dependent sys-
tematic bias in detected allele fractions across whole genomes.
We also seek to quantify its utility using results from its application
to five small whole genome sequencing (WGS) noncancer cohorts,
to detect how common these systematic biases are and the extent
to which they affect different genomic regions and to gauge
whether the systematic bias predictions from our method are sup-
ported by gold-standard reference data.
Results
Biased variant allelic fractions occur across the genome
and are persistent across individuals
Five separate ethnically mixed patient cohorts in the USA and UK
(Table 1) were previously sequenced under confidential conditions
using distinct WGS pipelines prior to this study by Personalis, Inc.
and the 100,000 Genomes Project. Incremental Databases
(IncDBs) were generated using these data, containing between-pa-
tient standard deviation of allelic fractions for each autosomal ge-
nomic locus and also the corresponding aggregate allelic fraction
values (Fig. 1), without maintaining any sample-specific infor-
mation. This ensured that individuals remained anonymous
during the quality control process of examining reads using an
IncDB. An aggregate allelic fraction was defined as the mean of
all of the allelic fractions across the pa-
tient cohort for that specific allele at a
specific single-nucleotide genomic posi-
tion. All patients were noncancer pa-
tients, and in addition, patients in data
sets 2–5 all had neurological disorders.
The main differences between data sets
were the use of the reference genome
GRCh37 for alignment in data sets 1
and 2, while GRCh38 was used for data
sets 3–5, and the use of BWA-MEM (Li
2013) for alignment in data set 1, while
the Isaac-aligner (Raczy et al. 2013) was
used in data sets 2–5. Since clinical se-
quencing facilities will continually up-
grade their sequencing pipelines with
new versions of algorithms and genome
builds as time goes on, we wanted to
make comparisons between different se-
quencing protocols in different cohorts
of patients. In order to verify our find-
ings, we also sequenced two additional
cohorts (data sets 4 and 5) using exactly
the same protocol as data set 3.
The observed relationship between
standard deviation and the aggregate al-
lelic fraction at each genomic locus was
Table 1. Overview of cohorts whole-genome sequenced and analyzed
Data set Source Individual genomes Genome build Sequencing Alignment
1 Personalis, Inc. (USA) 150 GRCh37 Illumina HiSeq X BWA-MEM 0.7.12
2 100,000 Genomes Project (UK) 215 GRCh37 Illumina HiSeq X Isaac-aligner (SAAC00776.15.01.27)
3–5 100,000 Genomes Project (UK) 645 GRCh38 Illumina HiSeq X Isaac-aligner (iSAAC-03.16.02.19)
Figure 1. Approach for detecting loci with systematic sequence bias: Alternative allele fractions are col-
lected from a cohort of individuals at every locus and aggregated into allele-specific summary statistics.
These aggregate allelic fractions and standard deviations at each genomic position are stored in the
Incremental Database (IncDB), which does not contain any patient-specific information. The 99.9% con-
fidence interval for expected standard deviation at each allelic fractionwas generated. Genomic positions
where the observed standard deviation was below the confidence interval expected were cataloged as
“suspect loci” and mapped to variant calls in clinically relevant genes. Prioritization of genes for diagnos-
tic and reporting purposes can be adjusted according to the presence of suspect loci.
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compared to the expecteddistribution assuming inherited variants
inHardy-Weinberg equilibrium in Figure 2A–C.We labeled the po-
sitions which fell below the 99.9% confidence interval of the
Mendelian model as ‘suspect loci’; ∼1%–3% of all autosomal loci
were suspect loci for at least one allele, which we define as unique
suspect loci in this study. The upper and lower 99.9% confidence
intervals of the expected Mendelian model are illustrated in
Supplemental Figure S1. In all five data sets, suspect loci aremostly
a lowallelic fraction(up to∼40%)butwithmuchlower standardde-
viations across samples compared to Mendelian variants with the
same allelic fractions. The distribution of allelic fractions at suspect
loci are illustrated in Supplemental Figure S2 for data sets 1–3.
Unique suspect loci were counted across data sets 1 and 2, and
the overlap revealed that most unique suspect loci were not
shared between both pipelines (Fig. 2D). Single nucleotide variants
(SNVs) that were called in the gold-standard reference NA12878,
an individual sample separate fromall of thedata setsused,were an-
alyzed to check if they validated both suspect locus positions
and their corresponding suspect alleles in data sets 1 and 2 (Fig.
2E). There were 147,000 SNVs reported in NA12878 that were also
annotated as suspect in both data sets 1 and2,which corresponded
to an overlap proportion roughly twice as high as in Figure 2D,
showing that suspect variant calls were more frequent at suspect
loci present in both data sets than in either one data set alone.
Enrichment of suspect loci within
specific genomic regions
Unique suspect loci were found to
be present across the entire sequenced
autosomal genome and only absent in
unsequenced sections, although their
prevalence varied across sequenced re-
gions both locally and showing larger
trends across chromosomes (Fig. 3). We
examined the distribution of unique
suspect loci across different regions of
the genome (Fig. 4) and recorded the re-
gional enrichment of unique suspect
loci (Supplemental Table S1) using odds
ratios (ORs). All odds ratios calculated
were highly statistically significant due
to the very large number of genomic
positions sampled, even when the odds
ratios were close to 1. The 95% confi-
dence interval lower and upper bounds
were both equal to the reported odds ra-
tios to three significant figures in all cas-
es. The highest/least significant P-value
recorded was for the enrichment of sus-
pect loci in the intellectual disability
gene panel in data set 2 (OR=1.01, P=
8.69×10−41). All other P-values ranged
from 10−322 to 10−79.
The 100 base-pair flanks of large
(≥20 bp) homopolymers were the most
heavily enriched for suspect loci by a
large amount (OR=23.29, 33.69, 30.37
for data sets 1, 2, 3). Small (<20 bp)
homopolymers’ 100 base-pair flanks
(OR=12.40, 5.99, 7.36), GC-rich regions
(OR=8.19, 6.47, 7.99), and Alu repeats
(OR=5.70, 6.74, 6.21) were also strongly
enriched for suspect loci. Large homopolymers (OR=1.93, 2.92,
1.84) and the RepeatMasker regions (OR=1.85, 2.96, 2.18) were
mildly enriched for suspect loci in data sets 1–3. Small homopoly-
mers, on the other hand,were depleted or unenriched (OR=0.525,
1.03, 0.519), and the NIST GIAB high-confidence region was
strongly depleted (OR=0.191, 0.154, 0.172) for suspect loci. The
NonUnique100 region showed much greater enrichment of sus-
pect loci in data sets 2 (OR=3.26) and 3 (OR=2.17), than in data
set 1 (OR=1.30), and segmental duplications also displayed this
(OR=1.17, 2.15, 1.74).
Systematic biases confirmed in the gold-standard reference
sample
Our analysis based on aggregate allele fraction statistics found the
presence of suspect loci in all cohorts. In order to confirm that
these loci occur independently from the samples examined, specif-
ic suspect loci were examined in the reference sample NA12878
cell line, which was sequenced and had variants called by
Personalis, Inc. using the same pipeline as data set 1 for compari-
son but which was not part of any of the data sets used to generate
the IncDBs. We divided the SNVs called using this pipeline into
groups based on whether they were annotated as suspect or non-
suspect, whether they occurred in the NIST GIAB benchmark
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Figure 2. Identification of suspect autosomal loci/allele combinations with persistent low allelic frac-
tions across patients. Observed and expected alternative allele fractions were estimated from five differ-
ent whole-genome sequenced cohorts: (A) Data set 1, (B) Data set 2, (C) Data set 3. For all loci in
autosomal chromosomes, the standard deviation and aggregate allelic fraction values from the IncDB
were plotted against each other in a density plot. The darker regions have the highest concentration
of loci. The red lines indicate the upper and lower boundaries of the 99.9% confidence interval for the
expected allelic standard deviation (shown in Supplemental Fig. S1A,B, respectively). Suspect loci for
each cohort were defined as the loci with standard deviation below their simulated model lower thresh-
old. A total of 2.8 billion autosomal loci were assessed. (D) Venn diagram showing the overlap of all sus-
pect loci between data sets 1 and 2. (E) Venn diagram of overlap at suspect loci where SNVs have been
called. A total of 3.44 million autosomal SNVs were not annotated as suspect in either data set 1 or 2.
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regions, and whether they matched the v3.3.2 NIST GIAB bench-
mark variants at those positions.
Suspect SNVs, which accounted for ∼5% of all SNV calls,
mostly reported low allele fractions (0.300 median compared to
0.579 in nonsuspect SNVs) in the read pileup of NA12878, with
the exception of suspect SNVs within the benchmark region that
matched the benchmark variants. These were the least common
type of suspect SNV andmost closely resembled the allelic fraction
distribution of nonsuspect SNVs (1358 SNVs) (Fig. 5A), suggesting
that suspect loci that matched the benchmark variants were likely
to be false positives. Suspect SNVs within the benchmark regions
usually did not match the benchmark variants within these
high-confidence regions (1839 SNVs) (Fig. 5B). Most suspect
SNVs occurred outside of the benchmark regions (23,802 SNVs)
(Fig. 5C).
In contrast, most called SNVs in NA12878 were nonsuspect,
were within the GIAB high-confidence benchmark region, and
matched the GIAB benchmark variants for those positions
(263,288 SNVs) (Fig. 5D). These conformed to the expected distri-
bution of allele fractions for heterozygous or homozygous SNVs,
with peaks around 50% and 100%. Nonsuspect SNVs that were in-
side the high-confidence benchmark region but which did not
match the benchmark variants were the least common and only
showed a peak around 100%, with no peak observed for heterozy-
gous variants and low levels of SNVs at all allelic fractions, suggest-
ing that these were sequenced the worst
of the nonsuspect loci (665 SNVs) (Fig.
5E). Nonsuspect SNVs outside of the
benchmark regions were also numerous
and had a similar pattern to nonsuspect
SNVs which matched benchmark vari-
ants, although the peaks were broader
(43,169 SNVs) (Fig. 5F), suggesting that
the allelic fractions recorded for these
were slightly less accurate.
Suspect loci called as SNVs occurred
across all types of genomic regions, in-
cluding clinically important positions
(Fig. 5G). Altogether, this suggests that
the systematic biases at suspect loci can
contribute to false positive variant calls
in clinically important regions, even
within the NIST GIAB high-confidence
regions. However, suspect SNVs that
match the v3.3.2 NIST GIAB benchmark
variants should be treated with caution,
since their allelic fraction distributions
suggest that these may indeed be true
variants, so the NIST GIAB benchmark
variants are a necessary and complemen-
tary resource to combine with IncDB-
basedmethods for annotating systematic
errors accurately.
Discussion
The main aim of this study has been to
develop and evaluate a novel statistical
method to identify positions of the ge-
nome that are prone to systematic bias
in genomic sequencing and alignment,
using anonymized summary patient
data. We developed an approach to quality control sequenced
reads in the autosomal genome by cataloging genomic positions
that persistently present a low-fraction alternate allele across pa-
tients rather than reflecting true biological variation, which we
have labeled as ‘suspect loci.’ We have explored the extent to
which these systematic biases occur across varied genomic regions,
including regions known to be difficult to sequence, higher confi-
dence regions, and clinical panels. We have also confirmed the ex-
istence of these systematic biases in an independent gold-standard
reference genome and the utility of our approach.
For the purposes of this paper, we have defined systematic bi-
ases as locus-specific errors in the accurate quantification of an al-
lelic fraction that affect all samples sequenced with the same
pipeline to a similar extent. Within this definition, our method
should successfully identify almost all single-nucleotide allelic
fraction biases >1.5%, but it does not have the sensitivity to detect
smaller biases at the confidence level chosen (Supplemental Fig.
S2). For example, using a confidence interval of 99.9% and a sam-
ple size of 150 (reflecting the parameters used to classify suspect
loci for data set 1), ∼9.6% of sites with a 1% systematic error rate
were classified as suspect loci, while ∼99.2%/99.8%/100%/100%
of sites with a 2%/3%/4%/5% systematic error rate were classified
as suspect loci, respectively, when we simulated sites with these
systematic error rates, representing a very high resolution. We
have not tested this method for identifying systematic biases in
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Figure 3. Variability in distribution of unique suspect loci in sequenced regions of Chromosome
1. Histograms show the numbers of suspect loci in 100 regular intervals across Chromosome 1, with
the number of suspect loci per 2.49-million-bp bin on the y-axis and the nucleotide position on the x-
axis. There were no suspect loci at the centromere since this could not be sequenced. The black dotted
line shows themean number of suspect loci per bin, while the red line shows the number of suspect loci in
each bin that would be expected by chance (1 per 1000 loci). (A) Data set 1, Personalis IncDB and
GRCh37. (B) Data set 2, 100,000 Genomes Project and GRCh37. (C) Data set 3, 100,000 Genomes
Project and GRCh38.
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the detection of indels or structural variants, but, with modifica-
tions, a similar approach could in theory be used to identify those
types of systematic error. We carried out Monte Carlo simulations
to check if this method could be used to identify CNVs, but found
that CNVs were not annotated by this method below a population
frequency of 10% and could only be detected if intervening SNV
alleles had unbalanced aggregate allelic fractions >10%.We expect
that CNVs that fulfill these criteria are exceedingly rare, so this is
unlikely to cause much of the systematic bias this method identi-
fies. Ourmethod cannot be used for identifying types of systematic
bias that are not locus-specific, such as general biases in the detec-
tion of certain alleles (e.g., GC bias) (Chen et al. 2013), biases that
systematically affect the ends of genomic reads being sequenced
(Ma et al. 2019), or other context-specific biases that do not occur
in a systematic or locus-specific manner. For example, we would
not expect to identify mosaicism unless this was systematic, with
a high proportion of individuals having the same alternative geno-
types at the same genomic coordinates in the same fraction of cells
in their tissue. To evaluate whether age-related mosaicism could
have been present in our results, we compared the numbers of sus-
pect loci (54.6 million) and suspect SNVs (43,832) in data set 5,
which used a more elderly cohort of patients, with data set 3
(63.2 million suspect loci and 46,287 suspect SNVs) and data
set 4 (90.3 million suspect loci and 59,634 suspect SNVs), which
both used the same sequencing pipeline. We did not observe
an increase in suspect loci in the gene TP53, which is thought to
be correlated with this (Yizhak et al.
2019), or in general across the genome
(Supplemental Fig. S3), so we could not
find evidence for mosaicism affecting
suspect locus annotation. The main
aim of our approach is not to identify a
specific cause of systematic bias but rath-
er to act as a quality control method, to
catalog where these systematic biases oc-
cur so that they can be filtered out of sci-
entific and clinical results where they
may lead to inaccurate conclusions. As
a result, our study does not seek to iden-
tify why the systematic biases we have
identified occur, even if some of our re-
sults suggest possible causes that could
be followed up by future studies.
To investigate the extent to which
differences in mutations between large
patient cohorts affected the annotation
of suspect loci when technical proce-
dures were held constant, we compared
the overlap between suspect loci for data
sets 3–5, for which all patients were se-
quenced using the same protocol and
pipeline. These three data sets showed
considerable suspect loci overlap (mean
overlap= 65.7%) and suspect SNV over-
lap (mean overlap=71.9%) in the inter-
section of all three data sets, although
there were some differences likely due
to private mutations (Supplemental Fig.
S3). Compared with the overlap between
data sets 1 and 2, for which separate tech-
nical procedures were used (mean over-
lap=34.8% for suspect loci, 66.4% for
suspect SNVs), the overlap was ∼30% greater for suspect loci but
only ∼5% greater for suspect SNVs, suggesting that differences in
the technical procedures used played a large role in suspect locus
annotation in general, but genetic differences between cohorts
were particularly important when identifying systematic biases
that could affect variant calls. We would therefore recommend us-
ers increase the size of IncDBs they generate as much as is reason-
ably possible, to maximize the numbers of systematic biases they
can detect by this method, at least until overlap between separate
IncDBs approaches a maximum percentage.
For loci unaffected by systematic bias, the standard deviation
and aggregate allelic fraction stored in the IncDB were expected to
relate to each other in accordance with Hardy-Weinberg equilibri-
um. However,∼1%–3% of autosomal loci had a significantly lower
standard deviation than predicted by Hardy-Weinberg equilibri-
um (P= 0.0005), suggesting the presence of systematic bias across
numerous genomic loci. At these loci, most individuals appear to
present a low-fraction allele. Persistent low-fraction alleles would
be inconsistent with our understanding of human genetics and
are presumably a technological artifact: a bias or systematic error
in the sequencing technology itself or perhaps in the read map-
ping. The impact of these suspect loci is magnified in the context
of studies looking at large numbers of genomic positions, since a
small percentage of this would still correspond to a high number
of genomic positions affected by systematic bias. It is therefore
clear that these systematic biases are of concern and deserve
BA
Figure 4. Enrichment of unique suspect loci in different types of genomic regions. All odds ratios
shown are statistically significant and equivalent to the 95% upper and lower confidence intervals to
three significant figures. (A) Log2 scale bar plot showing the odds ratios for regional enrichment of unique
suspect loci across all autosomal chromosomes from three different data sets. All odds ratios were calcu-
lated and shown to be significant using Fisher’s exact test. Regions were compared to “All sequenced re-
gions” (odds ratio of 1). (B) Bar plot showing the number of unique suspect loci per kb across all
autosomal chromosomes from three different data sets. Although clinical and high-confidence regions
had a lower rate of suspect loci per kb, over the entire genome they still contained a large number of sus-
pect loci overall in high-confidence regions (24.1/45.1/34.6 million in data sets 1, 2, and 3) and clinical
regions (2.55/4.64/3.55 million in data sets 1, 2, and 3 within the intellectual disability panel alone).
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further attention. Previous studies examining systematic sequenc-
ing bias have primarily focused on biases in total coverage across
loci and have not examined position-dependent systematic biases
in the allelic fraction (Cheung et al. 2011; Ross et al. 2013); there-
fore, no previous estimates for the prevalence of systematic se-
quencing bias in allelic fractions were available to compare with
our estimate of ∼1%–3% of all autosomal loci in the human
genome.
Our estimate indicated a very large number of genomic sites
affected by systematic bias, potentiallymore thanmight be expect-
ed. Therefore, we analyzed what proportion of these would be fil-
tered out by applying a strongly conservative confidence threshold
(99.999%) in addition to the default threshold used in this study
(99.9%) to data sets 1–3 and compared how this affected suspect
locus numbers, allelic fractions, and overlap between data sets 1
and 2. This filtered out a very high proportion (99.98%/91.06%/
92.68% in data sets 1, 2, and 3, respectively) of the suspect loci
that had allelic fractions <0.03, since it was rare for loci exhibiting
very small systematic biases to have a standard deviation lower
than the 99.999% confidence threshold (Supplemental Fig. S4)
compared to the 99.9% confidence threshold (Supplemental Fig.
S2). In contrast, amuch lower proportion
(25.95%/17.74%/23.40% in data sets 1,
2, and 3, respectively) of the suspect
loci with larger systematic biases (allelic
fractions>0.03) were filtered out at the
99.999% confidence threshold. Since it
is the larger systematic biases that are
most likely to affect variant calling, this
shows that themethod is robust for iden-
tifyingmost important systematic biases,
even at a strongly conservative confi-
dence level. The percentage overlap of
suspect loci between data sets 1 and 2 de-
creases slightly when a more conserva-
tive threshold (99.999% confidence
interval) is used for defining suspect
loci (from 47.9%/21.7% to 41.1%/
16.1% of data sets 1 and 2, respectively)
(Supplemental Fig. S5).
Suspect loci were widespread across
all sequenced chromosomal segments,
but there was variability between differ-
ent types of genomic region. Despite
this, there was little or no depletion of
suspect loci in some regions expected to
have more accurate sequencing, such as
exons and the clinical gene panels, sug-
gesting that greater caution in these areas
is justified when calling variants. The
NIST high-confidence regions displayed
the greatest depletion of suspect loci as
expected and had the lowest proportion
of suspect loci per kb, while homopoly-
mer flanks displayed the greatest enrich-
ment of suspect loci.
The correlation between chromo-
somal suspect locus density and the pro-
portions of chromosomes within large
homopolymer flanks was high (Spear-
man’s rho=0.955, 0.861, 0.820, P=5.11
×10−12, 2.76× 10−7, 3.07 ×10−6 for data
sets 1, 2, and 3, respectively), accounting for the majority of the
variability in the proportion of suspect loci in autosomal chromo-
somes (Supplemental Fig. S6). The flanks of large homopolymers
are particularly prone to errors in alignment compared to other
types of sequencing error, especially for Illumina sequencing
(Laehnemann et al. 2016) as was done here, suggesting that the
misalignment of reads could be a source of systematic biases.
One hundred base pairs was chosen as the flank length
because it is of the same order of size as the read lengths used for
the Illumina sequencing and we would not expect anything out-
side of 100 bp from a homopolymer to be covered by sequencing
reads, so the 100-bp length is the theoretical maximum length at
whichwemight expect effects to occur. Homopolymers cannot af-
fect the sequencing beyond one read length from their edge. In
practice, most suspect locus enrichment occurred within the
3-bp flanking regions however, with enrichment odds ratios great-
ly increasing when the flank size was reduced to 3 bp in both large
homopolymers (from 23.3/33.7/30.4 in data sets 1, 2, and 3, re-
spectively, in 100-bp flanks, to 171.3/94.3/97.6 in 3-bp flanks)
and small homopolymers (from 12.4/6.0/7.4 in 100-bp flanks in
data sets 1, 2, and 3, respectively, to 30.9/12.2/13.3 in 3-bp flanks).
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Figure 5. Suspect loci in detected variants of a gold-standard genome. Distribution of allelic fractions
of SNVs called in Chromosome 1 of NA12878, classified as either suspect SNVs (top row in A–C) in data
set 1 (Personalis), or nonsuspect SNVs (second row in D–F). SNVs were also classified based on whether
they matched the NIST GIAB v3.3.2 benchmark variants (left column), did not match the benchmark
variants (middle column), or were outside of the GIAB benchmark region (right column). Low coverage
variants (<10 supporting reads) were excluded from this analysis. (G) Cropped panels from the
Integrative Genomics Viewer (Robinson et al. 2017), highlighting suspect loci from data set 1 in
Chromosome 1 that were called as variants separately in NA12878. NA12878 was sequenced with
Illumina HiSeq but not used as part of the patient data set to create the IncDB (Zook et al. 2014,
2019). Reads are shown in gray with colored bands where nonreference allelic reads were observed
(A =green, C =blue, G =brown, T = red). Suspect SNVs and their respective read proportions in the
NA12878 cell line are indicated above; these systematically occur at similar levels across all patients
in the IncDBs used to identify them. (Left, middle) Suspect SNVs in exonic and intronic regions of genes
in the PanelApp intellectual disability panel (Martin et al. 2019). (Right) Suspect SNV in an intergenic
region.
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In addition, we found differences in regional systematic bias-
es between data sets. For example, the NonUnique100 region
showed much greater enrichment of suspect loci in data sets 2
(OR=3.26) and 3 (OR=2.17) than in data set 1 (OR=1.30). This re-
gion is defined as containing all sequenced positions where a sin-
gle 100-bp read cannot map uniquely, so we would expect a large
proportion of systematic biases here tomainly correspond to align-
ment errors rather than sequencing chemistry. The higher enrich-
ment of suspect loci in NonUnique100 in data sets 2 and 3 could
therefore indicate that the different aligners used (Isaac aligner
[Raczy et al. 2013] for data sets 2 and 3 rather than BWA-MEM
[Li 2013] for data set 1) could be the main explanation for the dif-
ferent levels of systematic bias found between the data sets in this
region. The Isaac aligner is known to be a faster aligner than BWA-
MEM, but previous validation attempts found that it was slightly
worse than BWA-MEM in terms of accuracy, especially outside of
NA12878 (Mainzer et al. 2015). The increased frequency of system-
atic biases we detected with the Isaac aligner in data sets 2 and 3
therefore seems to indicate that BWA-MEM is still superior in terms
of accuracy, at least comparedwith the versions of the Isaac aligner
used (SAAC00776.15.01.27 and iSAAC-03.16.02.19, respectively).
We also found great variability in the distribution of suspect
loci within individual genes tested (Supplemental Data S1, S2).
For example, within the clinical gene panels, there were very low
proportions of suspect loci (0% out of 2021 total loci in LIPT2 in
data set 2) to very high proportions of suspect loci (36.6% out of
3759 total loci in NPRL2 in data set 2), suggesting that some genes
might be particularly prone to systematic sequencing biases. This
is likely because the genes intersect with the problematic regions
we examined in different ways. Both of these genes are associated
with genetic epilepsy syndromes, but LIPT2 is not affected by sys-
tematic sequencing biases at all, while these heavily affect NPRL2.
Clinicians focusing on specific genes for diagnostic purposes could
use this information to identify how much caution they need
when assessing pathogenic variants in those genes (Table 2).
These suspect loci were confirmed in an independent reference
sample sequenced using the same pipeline, including within in-
trons, exons, intergenic regions, and NIST GIAB high-confidence
regions, and within called variants in clinically relevant regions
such as the PanelApp disease panels (Martin et al. 2019). In addi-
tion, we demonstrated that our approach could be used in combi-
nation with the NIST GIAB benchmarking variants to improve
suspect locus annotation by identifying which suspect SNVs
were likely to be false positives.
We further confirmed that suspect variants were filtered
out of the Genome Aggregation Database (gnomAD) using their
quality control processes (Supplemental Fig. S7). The gnomAD
database is a large database of all of the variation found across a
large ethnically diverse population, taken from 125,748 exomes
and 15,708 genomes (Karczewski et al. 2019). Our results revealed
that suspect variants were also widespread in the gnomAD
database, even after filtering by gnomAD’s quality control process,
across allelic frequencies. We also evaluated whether suspect
loci could be identified simply by using a quality threshold
(Supplemental Fig. S8). Nonsuspect loci had significantly higher
proportions of high quality reads, with >90% of reads having se-
quencing and mapping quality scores >20 in ∼90% of nonsuspect
loci. This demonstrated that low-quality reads were more frequent
among suspect loci to a large degree, suggesting that improving se-
quencing and alignment quality could help with decreasing these
systematic biases. However, there was still significant overlap be-
tween read quality at suspect and nonsuspect loci. Finally, we an-
alyzed whether read depth could be used to quality-control for
suspect loci (Supplemental Fig. S9). Kolmogorov–Smirnov tests
confirmed that there was a different distribution of read depths be-
tween the sets of genomic positions with and without suspect loci
(D=0.4289, 0.2885, 0.3079 and P<10−15 for data sets 1, 2, and 3,
respectively), but there was not a clear correlation between read
depth and likelihood of a position having suspect loci. While the
lower quartile and median values for read depth were slightly low-
er for unique suspect loci, for data sets 2 and 3 the upper quartiles
were significantly higher at unique suspect loci. We could only
Table 2. Suspect loci found in data sets 3–5 that have been included in diagnostic gene panels and verified as pathogenic variants in ClinVar
dbSNP ID Gene affected Variant type Diagnostic panel ClinVar associated disease
rs1131691563 AMPD2 Splice donor variant Ataxia and cerebellar anomalies Not provided
rs1553201258 DARS2 Intron variant Ataxia and cerebellar anomalies Cerebral cortical atrophy
rs370132645 OTOF Splice donor variant Auditory neuropathy spectrum disorder Rare genetic deafness
rs587779190 MSH2 Stop gained Adult solid tumors cancer susceptibility Lynch syndrome
rs63750640 MSH2 Missense variant Adult solid tumors cancer susceptibility Lynch syndrome
rs1114167845 MSH2 Stop gained Adult solid tumors cancer susceptibility Lynch syndrome
rs587779197 MSH2 Missense variant Adult solid tumors cancer susceptibility Lynch syndrome
rs587779195 MSH2 Splice donor variant Adult solid tumors cancer susceptibility Lynch syndrome
rs121918737 SCN1A Missense variant Genetic epilepsy syndromes Severe myoclonic epilepsy in infancy
rs267607819 MLH1 Splice acceptor variant Adult solid tumors cancer susceptibility Lynch syndrome
rs1559551570 MLH1 Frameshift Adult solid tumors cancer susceptibility Hereditary nonpolyposis colon cancer
rs148891849 DNAH5 Stop gained Primary ciliary disorders Primary ciliary dyskinesia
rs7755898 CYP21A2 Stop gained Disorders of sex development Classic congenital adrenal hyperplasia
rs1554247637 ARID1B Frameshift Coffin-Siris syndrome Inborn genetic diseases
rs1562671039 PMS2 Stop gained Adult solid tumors cancer susceptibility Not provided
rs193929376 GCK Splice donor variant Diabetes – neonatal onset Permanent neonatal diabetes mellitus
rs121909112 HSPB1 Missense variant Distal myopathies Charcot-Marie-Tooth disease type 2F
rs111033565 PRSS1 Missense variant Pancreatitis Hereditary pancreatitis
rs794728419 KCNH2 Splice donor variant Short QT syndrome Not provided
rs587777641 GPIHBP1 Missense variant Severe hypertriglyceridemia Hyperlipoproteinemia, type ID
rs1563963464 APTX Splice acceptor variant Ataxia and cerebellar anomalies Ataxia-oculomotor apraxia type 1
rs146292819 ABCA1 Missense variant Hereditary neuropathy ABCA1-related disorders
rs864321692 WAC Stop gained Intellectual disability Desanto-Shinawi syndrome
rs587782455 PTEN Splice acceptor variant Adult solid tumors for rare disease PTEN hamartoma tumor syndrome
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conclude that there was a greater breadth of read depth in posi-
tions annotated as unique suspect loci than other positions. A pos-
sible explanation for our results could be that most unique suspect
loci have slightly lower read depths than nonsuspect loci, but
some unique suspect loci have extremely high read depth, perhaps
as a result of systematic alignment errors attributing reads from
multiple locations in the genome to the same genomic position
at these suspect loci. Our analyses therefore suggest that the exist-
ing read depth thresholds and quality control procedures com-
monly used in sequencing would not be sufficient to filter out
the systematic biases, and the reported variants in large population
studies such as gnomAD may need to be reassessed.
We have demonstrated the utility of IncDBs to assess the
quality of clinical whole genomes of five independent cohorts se-
quenced by commercial and public healthcare organizationswhile
maintaining patient anonymity. In addition to showing the utility
of this approach on whole-genome Illumina sequencing, IncDBs
could be applied to data from different types of sequencing plat-
forms in the future, including specific targeted, exome-sequenc-
ing, and long-read technologies such as Pacific Biosciences
(PacBio) and Oxford Nanopore. Our agile approach for detecting
suspect loci could be deployed in various settings where the raw
data for individual genomes cannot be accessed—for instance,
when patient confidentiality must be maintained. Under those
conditions, being able to identify systematic biases would enable
improvements to variant calling andhas the potential to reduce er-
rors in clinical genomic testing.
Methods
Data sources
Data set 1 (Personalis, Inc.)
WGS data were obtained by Personalis, Inc. using Illumina HiSeq
and the standard library prep and sequencing protocol. Paired-
end reads of 100-bp length were mapped with BWA-MEM
(Li 2013) to align reads against the GRCh37 reference human ge-
nome (Table 1). The mean depth of coverage across patients was
45×. There were 150 noncancer individuals in the cohort, includ-
ing triplets (infant and two parents) recruited fromhospitals in the
USA and a mix of ethnicities, but specific age or ethnic data were
not available.
Data set 2 (100,000 Genomes Project)
Blood samples were taken from 215 distinct patients of mixed
ethnicities with noncancer neurological diseases in each cohort,
recruited from hospitals in the UK. The libraries were prepared us-
ing Illumina TrueSeq DNA PCR-Free Library Prep for the majority
of the samples. For a small proportion of samples, when the con-
centration was <20 ng/µL at Illumina, the Nano DNA library
prep method was used. All main program samples were sequenced
using 150-bp length paired-end sequencing on HiSeq X, and
the mean depth of coverage across patients was 30×. WGS data
were obtained by Genomics England’s 100,000 Genomes Project,
using Illumina HiSeq sequencing and mapped with the Illumina
Isaac-aligner (version SAAC00776.15.01.27) (Raczy et al. 2013) to
align reads against the GRCh37 reference human genome. All var-
iants were called using Isaac Variant Caller (Starling, v2.1.4.2)
(Raczy et al. 2013) and annotated using Ensembl database (v72)
(Cunningham et al. 2019). The median age of patients was 13 yr
(Supplemental Fig. S10).
Data sets 3, 4, and 5 (100,000 Genomes Project)
No patients were in multiple data sets. Blood samples were collect-
ed and library-prepped in the same way as data set 2. WGS data
were obtained by Genomics England’s 100,000 Genomes Project,
using Illumina HiSeq sequencing and mapped with the Illumina
Isaac-aligner (iSAAC-03.16.02.19) to align reads against the
GRCh38 reference human genome. The reads were aligned by
Illumina with the Illumina Isaac-aligner (v03.15.09.04) and vari-
ants called by Isaac Variant Caller (Starling, v2.3.13) (Raczy et al.
2013) with annotation by Ensembl (v81) (Cunningham et al.
2019). Data sets 3, 4, and 5 all used 215 distinct patient samples
from the noncancer neurological diseases cohort, but the patients
in data sets 3 and 4 were randomly sampled, so these data sets can
be treated as technical replicates. For data set 5, we used data from
the same cohort but selected all of the oldest patients available
since the patients in data sets 3 and 4 were generally very young.
The age distributions of patients in cohorts 2–5 are illustrated in
Supplemental Figure S10 and had median ages of 13, 16, 13, and
64 yr, respectively. The numbers of patients across different ethnic
categories in data sets 2–5were recorded in Supplemental Table S2.
Incremental Database Generation
The read depth values for each allele (A, C, G, T) at every autosomal
genomic locus were calculated from aligned BAMs and divided by
the total read depth at the corresponding loci to get the allelic cov-
erage fraction, xp, for each allele at each locus in each patient.
Individual IncDBswere created for each data set from the aggregate
allelic fraction and standard deviation values for each allele at each
locus across the entire cohort, which were calculated from xp as de-
scribed below:
Aggregate allelic fraction = 1
N
∑N
p=1
xp, (1)
Standard deviation =

1
N
∑N
p=1
(xp − x)2
√√√√
=

1
N
∑N
p=1
(x2p )−
1
N
∑N
p=1
xp
⎛
⎝
⎞
⎠
2
√√√√√ . (2)
N is the number of patients, p is the patient identifier, xp is the al-
lelic coverage fraction for a specific allele in patient p, and x is the
mean of all of the allelic coverage fractions for that same allele
across all patients (aggregate allelic fraction).
Notice that to compute the aggregate allelic fraction, we do
not store each individual’s xp values but the sum of xp across all in-
dividuals. Similarly, we can compute the standard deviation across
individuals by storing the sum of xp , as well as the sum of xp
2. This
approach not only removes all individual-specific genomic infor-
mation but also allows the IncDB to grow indefinitely, as more
samples are sequenced and analyzed: They can simply contribute
to the running sums of xp and xp
2. Also, note that the sums in the
equations above do not take up more size on the disk as the num-
ber of samples increases, so the overall IncDB file size does not in-
crease as new samples are added.
Identifying loci affected by systematic bias (suspect loci)
For each locus in all autosomal chromosomes, the standard devia-
tionandaggregate allelic fractionvalueswere taken fromthe IncDB
and plotted against each other in a density plot usingMATLAB 9.6,
R2019a (www.mathworks.com/downloads). The main bow-
shaped feature of this plot (Fig. 2A–C) was the expected result of
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Mendelian alleles in the human population, present at a variety of
population frequencies, while observed loci with standard devia-
tions below the 99.9% expected confidence interval for a given nu-
cleotide were defined as suspect loci for that allele. Autosomal
positions that displayed at least one suspect allele at that position
were termed unique suspect loci. The total count of unique suspect
loci was therefore lower than the total count of allele-specific sus-
pect loci, since some positions had multiple suspect alleles.
The 99.9% confidence interval was estimated using Monte
Carlo sampling as detailed in the pseudocode below. Monte
Carlo sampling used three nested loops which respectively simu-
lated the standard deviation at a single genomic locus between n
individual patient allelic fractions (loop 3), 1000 times to calculate
the upper and lower 99.9% confidence intervals (loop 2), for each
aggregate allelic fraction from 0 to 1 in intervals of 0.01 (loop 1).
The standard deviation values were recorded and used to classify
suspect loci as visually illustrated (Fig. 2A–C); n=150 for data set
1, and n=215 for data sets 2/3. The model assumed an error rate
of 0.01, corresponding to an approximation of the error rate
of Illumina WGS (Wall et al. 2014). Approximately 90% of geno-
mic reads in data set 1 had a quality score of 20 or above, corre-
sponding to this error rate (Supplemental Fig. S8). Decreasing the
assumed error rate increases the numbers of sites with very low
systematic allelic biases that get annotated as suspect loci by
increasing the standard deviation threshold for classification as
suspect (Supplemental Fig. S11). The distribution of the suspect lo-
cus allelic fractions at an assumed error rate of 0 are illustrated in
Supplemental Figure S12, for comparison with the allelic fractions
at an assumed error rate of 0.01 (Supplemental Fig. S2).
Monte Carlo simulation of standard deviation (pseudocode)
1. For aggregate allelic fractions, AAF, from 0 to 1 in intervals of
0.01 (each representing a simulated single autosomal genomic po-
sition with that aggregate allelic fraction across all patients) do {
2. repeat 1000 times {
3. repeat for n simulated patients {
Randomly generate diploid genotype for each simu-
lated patient using the binomial distribution (assuming two al-
leles) at the given AAF value;
Assuming a sequencing error rate of 0.01, randomly
draw c reads from the binomial distribution to simulate observed
major/minor allelic reads for the simulated diploid genotype;
Divide by total read depth, c, to get the individual al-
lelic fractions for each patient;
}
Calculate the standard deviations between the individual
allelic fractions for all n patients at the simulated genomic
position;
}
Maximumandminimumvalues of 1000 repetitionsmark up-
per and lower 99.9% confidence intervals for standard deviation at
given AAF;
}
Analysis of regional enrichment of unique suspect loci
Histograms of suspect locus density across Chromosome 1 were
plotted in MATLAB alongside chromosome ideograms taken
from the UCSC Genome Browser (Kent et al. 2002) (GRCh37,
http://hgdownload.cse.ucsc.edu/goldenpath/hg19/database/
cytoBandIdeo.txt.gz; and GRCh38, http://hgdownload.cse
.ucsc.edu/goldenpath/hg38/database/cytoBandIdeo.txt.gz)
in order to show suspect locus density in comparison with
chromosomal banding patterns.
BED files for 18 different types of genomic region were ana-
lyzed to check enrichment of unique suspect loci using a Fisher’s
exact test to calculate the exact significance values. Full contingen-
cy tables for all regions in data sets 1–3 (autosomal chromosomes
only) are available in Supplemental Table S1 to show how these
were calculated.
The regions tested were the NIST GIAB high-confidence
regions, Alu repeats, GCgt70 (>70% GC content) regions,
NonUnique100 regions (defined as all regions where a single
100-bp read could not map uniquely), segmental duplications,
small/large homopolymers, flanking regions of small/large homo-
polymers, the RepeatMasker region, introns, exons, genes, inter-
genic regions, ClinVar short variants, and three neurological
clinical panels (see next section for full list and details of BED files
used).
“All sequenced regions” referred to all genomic loci where the
number of aligned reads was greater than zero. There were no sus-
pect loci outside of this region by definition, so the odds ratiowas 1
by default.
Genomic region BED file sources
NIST GIAB high-confidence region (Xiao et al. 2014; Zook et al.
2014, 2019)—a selection of genomic loci covering the majority
of the humangenome that are considered to havehigh-confidence
calls (ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/NA12878_
HG001/latest/GRCh37/HG001_GRCh37_GIAB_highconf_CG-Ill
FB-IllGATKHC-Ion-10X-SOLID_CHROM1-X_v.3.3.2_highconf_
nosomaticdel.bed).
NonUnique100—all regions where a single 100-bp read can-
not map uniquely (so all stretches on the reference that are 100
bp or longer that are repeated on the GRCh37 reference).
Segmental duplication—long DNA sequences (>10 kb) that
are found in multiple locations across the human genome as a re-
sult of duplications.
GCgt70, small/large homopolymers and their 100-bp flank-
ing regions were all calculated as described below, and BED files
(available at https://doi.org/10.15131/shef.data.9927053) were
generated in-house rather than downloaded from another source.
GCgt70 (GC content > 70%)—regions with >70% GC con-
tent. Loci were annotated as within this region if the surrounding
100 bp around each locus had >70% GC content.
Small/large homopolymer—region of DNA containing a
single nucleotide (9–19 bp for small homopolymers, ≥20 bp for
large homopolymers).
Small/large homopolymer flanks—100-bp flanks surround-
ing the small/large homopolymer regions, respectively.
RepeatMasker region—a BED file containing a variety of
different types of repeats (Smit et al. 2013–2015). The open-3-2-7
version of RepeatMasker was downloaded from the UCSC Table
Browser (https://genome.ucsc.edu/cgi-bin/hgTables) (Karolchik
et al. 2004).
Alu repeats (Hasler and Strub 2007)—the most common
type of transposable element in the human genome, of which
there are over one million copies. The BED file was composed of
all RepeatMasker Regions downloaded from the UCSC Table
Browser (https://genome.ucsc.edu/cgi-bin/hgTables) that were an-
notated as Alu repeats in the repName column.
BED files were also downloaded for genic regions, intergenic
regions, exonic regions, intronic regions (March 22, 2019), and
ClinVar short variants (June 12, 2019), acquired from the UCSC
Table Browser (https://genome.ucsc.edu/cgi-bin/hgTables).
Clinical panel BED files were also downloaded for the three
most reviewed neurological clinical panels on PanelApp (Martin
et al. 2019) (for intellectual disability [October 19, 2018], genetic
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epilepsy syndromes [February 7, 2019], and hereditary spastic
paraplegia [February 7, 2019], respectively; https://panelapp
.genomicsengland.co.uk/panels/).
Calculating allelic fractions at suspect loci in NA12878
An indexed BAM file for NA12878 Chromosome 1, sequenced us-
ing the same pipeline used in data set 1, was provided by
Personalis, Inc. We used the Integrative Genomics Viewer (IGV)
(Robinson et al. 2017) to examine NA12878’s read pileup at data
set1 suspect locuspositionsatwhichChromosome1SNVshadpre-
viously been called, to confirm that NA12878 exhibited low-frac-
tion alleles at these positions. NA12878 was not part of any
cohorts used to build the IncDBs in this study. Chromosome 1
SNVs in NA12878 were extracted from a VCF file corresponding
to the sequencing pipeline used for data set 1, which was also pro-
vided by Personalis, Inc. SNVs were classified as suspect if they cor-
responded to the same alleles at the same positions as suspect loci
calculated for data set 1. The allelic fractions for these variants
were calculated from the NA12878 BAM file using SAMtools v1.9
(http://www.htslib.org/download/) mpileup (Li et al. 2009; Li
2011). Variants with fewer than 10 supporting reads were deemed
to have insufficient coverage and were not included.
Analyzing the proportion of gnomAD SNVs that are suspect
A list of all gnomAD variants (Karczewski et al. 2019), along
with their allelic fraction and annotation as PASS-flagged or not,
was obtained from a TSV file (available at https://doi.org/10
.15131/shef.data.9927062). This was filtered to only include
autosomal SNVs. These were classified as suspect and nonsuspect
SNVs as above. Variants in gnomAD were annotated as PASS
variants if they were marked this way in gnomAD v2.1 (https://
macarthurlab.org/2018/10/17/gnomad-v2-1/).
Comparing sequencing quality between suspect
and nonsuspect loci
The coverage of different allelic reads across all loci/nucleotide
combinations on Chromosome 1 was available for data set 1
(Cov), along with the corresponding coverage of allelic reads fil-
tered to only include reads with sequencing and mapping quality
scores greater than 20 (Cov20). The filtered coverage values of alle-
lic reads (Cov20) were divided by the corresponding unfiltered
coverage values (Cov) to get the proportion of allelic reads with se-
quencing andmapping quality scores both greater than 20 at each
locus/nucleotide combination. The cumulative distributions of
these valueswere calculated separately for locus/nucleotide combi-
nations that were annotated as suspect loci or nonsuspect loci.
Using suspect loci to check the quality of your own
sequenced samples
To address the limitations of existing quality control procedures
used in WGS and variant calling pipelines discussed in this study,
wehave created resources for researchers and clinicians to carry out
quality control of suspect variants occurring at positions that
show a consistent systematic allelic bias (see “Data access”). We
have provided BED files containing all of the suspect loci that we
have identified in all five data sets used for every allele, along
with their corresponding aggregate allelic fractions, standard devi-
ation between individuals’ allelic fractions, and allelic fractions
corresponding to z values of −2, −1, +1, and +2. We suggest that
researchers and clinicians using sequencing pipelines that are
similar to any of the three pipelines used in this study identify
the corresponding BED files and check the allelic fractions of any
variants that they have previously called that are present in these
BED files. If the allelic fraction of a called variant is not signifi-
cantly greater than would be obtained by systematic bias alone,
i.e., if it is lower than the suspect allelic fraction at a z value of
+1 for a milder filter or +2 for a stricter filter, then we would advise
annotating or even removing that called variant. Researchers can
also design custom filters based on their own preference if they
wish to use different z value thresholds or other combinations of
information. Researchers who are using Illumina WGS pipelines
that have less in common with the pipelines shown here may
also use a more conservative BED file of suspect loci to filter their
data, containing only suspect loci found in both data sets 1 and
2, which is also included in the data set.
The suspect loci BED files provided by this study were only
generated for specific WGS pipelines using Illumina HiSeq, and
it is unlikely that these results could be used reliably for quality
control of sequencing and alignment pipelines that are not similar
to these. We would therefore recommend that researchers who
have access to sequence data from a large cohort of patients should
develop their own IncDB and calculate suspect loci for their se-
quencing pipelines based on that. The drawback of this, as op-
posed to using the suspect loci BED files above, is that this is
computationally demanding and requires that researchers have ac-
cess to large sequence data sets for their pipeline.
Data access
Links to the sources of all nonconfidential data used in this article
are referenced in the text at first mention and also below. We do
not provide public links to download the raw sequence data we
used in this study to generate the IncDBs for individual genome
sequences since these are confidential. Data set 1 individuals were
sequenced for commercial purposes. While raw sequence reads
are no longer accessible for data set 1, we provide summary
statistics from the BAM files stored in the Incremental Database
(link below). In order to protect participants in data sets 2 and 3,
the 100,000 Genomes Project data can only be accessed through
a secure research environment. To access the data for research,
you must be a member of the Genomics England Clinical
Interpretation Partnership (GeCIP), the research community set
up to analyze the Project data. You can apply to join the GeCIP
(https://www.genomicsengland.co.uk/join-a-gecip-domain/). To
be eligible for data access, you must have your affiliation verified
at an institution that has signed the GeCIP Participation Agree-
ment and have your application to join a valid GeCIP domain
accepted by the domain lead or a member of the GeCIP team.
The Incremental Database containing the variant summary statis-
tics at all loci for each data set is available for download at https
://doi.org/10.15131/shef.data.9995945, and the gnomAD TSV file
generated in this study is available for download at https://doi
.org/10.15131/shef.data.9927062. The code used to generate and
analyze the IncDBsused in this study ispubliclyavailable atGitHub
(https://github.com/tmfreeman400/IncDB_code) and as Supple-
mental Code.
Genomics England Research Consortium
John C. Ambrose,6 Prabhu Arumugam,6 Emma L. Baple,6
Marta Bleda,6 Freya Boardman-Pretty,6,7 Jeanne M. Boissiere,6
6Genomics England, London EC1M 6BQ, UK
7William Harvey Research Institute, Queen Mary University of London, London
EC1M 6BQ, UK
Freeman et al.
424 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on August 12, 2020 - Published by genome.cshlp.orgDownloaded from 
Christopher R. Boustred,6 Mark J. Caulfield,6,7 Georgia C. Chan,6
Clare E.H. Craig,6 Louise C. Daugherty,6 Anna de Burca,6
Andrew Devereau,6 Greg Elgar,6,7 Rebecca E. Foulger,6 Tom
Fowler,6 Pedro Furió-Tarí,6 Joanne M. Hackett,6 Dina Halai,6
Angela Hamblin,6 Shirley Henderson,6,7 James E. Holman,6 Tim
J.P. Hubbard,6 Kristina Ibáñez,6,7 Rob Jackson,6 Louise J.
Jones,6,7 Dalia Kasperaviciute,6,7 Melis Kayikci,6 Lea Lahnstein,6
Kay Lawson,6 Sarah E.A. Leigh,6 Ivonne U.S. Leong,6 Javier F.
Lopez,6 Fiona Maleady-Crowe,6 Joanne Mason,6 Ellen M.
McDonagh,6,7 Loukas Moutsianas,6,7 Michael Mueller,6,7 Nirupa
Murugaesu,6 Anna C. Need,6,7 Chris A. Odhams,6 Christine
Patch,6,7 Daniel Perez-Gil,6 Dimitris Polychronopoulos,6 John
Pullinger,6 Tahrima Rahim,6 Augusto Rendon,6 Pablo Riesgo-
Ferreiro,6 Tim Rogers,6 Mina Ryten,6 Kevin Savage,6 Kushmita
Sawant,6 Richard H. Scott,6 Afshan Siddiq,6 Alexander Sieghart,6
Damian Smedley,6,7 Katherine R. Smith,6,7 Alona Sosinsky,6,7
William Spooner,6 Helen E. Stevens,6 Alexander Stuckey,6
Razvan Sultana,6 Ellen R.A. Thomas,6,7 Simon R. Thompson,6
Carolyn Tregidgo,6 Arianna Tucci,6,7 Emma Walsh,6 Sarah A.
Watters,6 Matthew J. Welland,6 Eleanor Williams,6 Katarzyna
Witkowska,6,7 Suzanne M. Wood,6,7 and Magdalena Zarowiecki6
Competing interest statement
J.H. is an employee and shareholder of Personalis, Inc.
Acknowledgments
Funding support for the analysis and methods development was
from the Medical Research Council (MRC) Proximity to
Discovery (P2D) Research Scheme and the National Institute for
Health Research (NIHR) Sheffield Biomedical Research Centre
(BRC). Additional funding was provided by the Academy of
Medical Sciences (SBF004/1052). The views expressed are those
of the author(s) and not necessarily those of the National Health
Service (NHS), the NIHR, or the Department of Health and Social
Care (DHSC). This research was also made possible through access
to the data and findings generated by the 100,000 Genomes
Project. The 100,000 Genomes Project is managed by Genomics
England Limited (a wholly owned company of the Department
of Health). The 100,000 Genomes Project is funded by the
National Institute for Health Research and NHS England. The
Wellcome Trust, Cancer Research UK, and the Medical Research
Council have also funded research infrastructure. The 100,000
Genomes Project uses data provided by patients and collected by
the National Health Service as part of their care and support. The
authors thank Mark Pratt, who initially proposed the concept of
the Incremental Database. The authors also thank Matt Parker
and the Sheffield Bioinformatics Core for their advice on data
processing.
References
The 1000 Genomes Project Consortium. 2010. A map of human genome
variation from population-scale sequencing. Nature 467: 1061–1073.
doi:10.1038/nature09534
Benjamini Y, Speed TP. 2012. Summarizing and correcting the GC content
bias in high-throughput sequencing. Nucleic Acids Res 40: e72. doi:10
.1093/nar/gks001
Chen Y-C, Liu T, Yu C-H, Chiang T-Y, Hwang C-C. 2013. Effects of GC bias
in next-generation-sequencing data on de novo genome assembly. PLoS
One 8: e62856. doi:10.1371/journal.pone.0062856
Cheung M-S, Down TA, Latorre I, Ahringer J. 2011. Systematic bias in high-
throughput sequencing data and its correction by BEADS. Nucleic Acids
Res 39: e103. doi:10.1093/nar/gkr425
Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM,
Bennett R, Bhai J, Billis K, Boddu S, et al. 2019. Ensembl 2019. Nucleic
Acids Res 47: D745–D751. doi:10.1093/nar/gky1113
Goldfeder RL, Priest JR, Zook JM, Grove ME, Waggott D, Wheeler MT,
Salit M, Ashley EA. 2016. Medical implications of technical accuracy
in genome sequencing. Genome Med 8: 24. doi:10.1186/s13073-016-
0269-0
Hasler J, Strub K. 2007. Survey and summary: Alu elements as regulators
of gene expression. Nucleic Acids Res 35: 1389. doi:10.1093/nar/
gkm044
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q,
Collins RL, Laricchia KM, Ganna A, Birnbaum DP, et al. 2019.
Variation across 141,456 human exomes and genomes reveals the spec-
trum of loss-of-function intolerance across human protein-coding
genes. bioRxiv doi:10.1101/531210
Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D,
Kent WJ. 2004. The UCSC Table Browser data retrieval tool. Nucleic
Acids Res 32: D493–D496. doi:10.1093/nar/gkh103
KentWJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler
AD. 2002. The Human Genome Browser at UCSC. Genome Res 12: 996–
1006. doi:10.1101/gr.229102
KingDA, SifrimA, Fitzgerald TW, Rahbari R, Hobson E, Homfray T,Mansour
S, Mehta SG, Shehla M, Tomkins SE, et al. 2017. Detection of structural
mosaicism from targeted and whole-genome sequencing data. Genome
Res 27: 1704–1714. doi:10.1101/gr.212373.116
Laehnemann D, Borkhardt A, McHardy AC. 2016. Denoising DNA
deep sequencing data—high-throughput sequencing errors and
their correction. Brief Bioinform 17: 154–179. doi:10.1093/bib/
bbv029
Li H. 2011. A statistical framework for SNP calling, mutation discovery, as-
sociationmapping and population genetical parameter estimation from
sequencing data. Bioinformatics 27: 2987–2993. doi:10.1093/bioinfor
matics/btr509
Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs
with BWA-MEM. arXiv:1303.3997 [q-bio.GN].
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G,
Abecasis G, Durbin R; 1000 Genome Project Data Process-
ing Subgroup. 2009. The Sequence Alignment/Map format and
SAMtools. Bioinformatics 25: 2078–2079. doi:10.1093/bioinformatics/
btp352
MaX, Shao Y, Tian L, Flasch DA,Mulder HL, EdmonsonMN, Liu Y, Chen X,
Newman S, Nakitandwe J, et al. 2019. Analysis of error profiles in deep
next-generation sequencing data. Genome Biol 20: 50. doi:10.1186/
s13059-019-1659-6
Mainzer LS, Chapman BA, Hofmann O, Rendon G, Stephens ZD, Jongeneel
V. 2015. Validation of Illumina’s Isaac variant calling workflow. bioRxiv
doi:10.1101/031021
Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O,
Leong IUS, Smith KR, Gerasimenko O, Haraldsdottir E, et al. 2019.
PanelApp crowdsources expert knowledge to establish consensus diag-
nostic gene panels. Nat Genet 51: 1560–1565. doi:10.1038/s41588-
019-0528-2
Raczy C, Petrovski R, Saunders CT, Chorny I, Kruglyak S, Margulies EH,
Chuang H-Y, Källberg M, Kumar SA, Liao A, et al. 2013. Isaac: ultra-
fast whole-genome secondary analysis on Illumina sequencing plat-
forms. Bioinformatics 29: 2041–2043. doi:10.1093/bioinformatics/
btt314
Robinson JT, Thorvaldsdóttir H, Wenger AM, Zehir A, Mesirov JP. 2017.
Variant review with the Integrative Genomics Viewer. Cancer Res 77:
e31–e34. doi:10.1158/0008-5472.CAN-17-0337
Ross MG, Russ C, Costello M, Hollinger A, Lennon NJ, Hegarty R, Nusbaum
C, Jaffe DB. 2013. Characterizing and measuring bias in sequence data.
Genome Biol 14: R51. doi:10.1186/gb-2013-14-5-r51
Sandmann S, de Graaf AO, Karimi M, van der Reijden BA, Hellström-
Lindberg E, Jansen JH, Dugas M. 2017. Evaluating variant calling tools
for non-matched next-generation sequencing data. Sci Rep 7: 43169.
doi:10.1038/srep43169
Smit AFA, Hubley R, Green P. 2013–2015. RepeatMasker Open-4.0. http
://www.repeatmasker.org.
Vattathil S, Scheet P. 2016. Extensive hidden genomic mosaicism revealed
in normal tissue. Am J Hum Genet 98: 571–578. doi:10.1016/j.ajhg
.2016.02.003
Wall JD, Tang LF, Zerbe B, Kvale MN, Kwok P-Y, Schaefer C, Risch N.
2014. Estimating genotype error rates from high-coverage next-genera-
tion sequence data. Genome Res 24: 1734–1739. doi:10.1101/gr.168393
.113
Genomic loci prone to systematic sequencing bias
Genome Research 425
www.genome.org
 Cold Spring Harbor Laboratory Press on August 12, 2020 - Published by genome.cshlp.orgDownloaded from 
XiaoC, Zook J, Trask S, Sherry S, theGenome-in-a-Bottle Consortium. 2014.
Abstract 5328: GIAB: genome reference material development resources
for clinical sequencing. Cancer Res 74: 5328. doi:10.1158/1538-7445
.am2014-5328
Yizhak K, Aguet F, Kim J, Hess JM, Kübler K, Grimsby J, Frazer R, Zhang H,
Haradhvala NJ, Rosebrock D, et al. 2019. RNA sequence analysis reveals
macroscopic somatic clonal expansion across normal tissues. Science
364: eaaw0726. doi:10.1126/science.aaw0726
Zook JM, Chapman B, Wang J, Mittelman D, Hofmann O, Hide W, Salit M.
2014. Integrating human sequence data sets provides a resource of
benchmark SNP and indel genotype calls. Nat Biotechnol 32: 246–251.
doi:10.1038/nbt.2835
Zook JM, McDaniel J, Olson ND, Wagner J, Parikh H, Heaton H, Irvine SA,
Trigg L, Truty R,McLean CY, et al. 2019. An open resource for accurately
benchmarking small variant and reference calls.Nat Biotechnol 37: 561–
566. doi:10.1038/s41587-019-0074-6
Received July 31, 2019; accepted in revised form February 14, 2020.
Freeman et al.
426 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on August 12, 2020 - Published by genome.cshlp.orgDownloaded from 
 10.1101/gr.255349.119Access the most recent version at doi:
2020 30: 415-426 originally published online March 10, 2020Genome Res. 
  
Timothy M. Freeman, Genomics England Research Consortium, Dennis Wang, et al. 
  
whole genomes
Genomic loci susceptible to systematic sequencing bias in clinical
  
Material
Supplemental
  
 http://genome.cshlp.org/content/suppl/2020/03/10/gr.255349.119.DC1
  
References
  
 http://genome.cshlp.org/content/30/3/415.full.html#ref-list-1
This article cites 27 articles, 7 of which can be accessed free at:
  
License
Commons 
Creative
.http://creativecommons.org/licenses/by-nc/4.0/described at 
a Creative Commons License (Attribution-NonCommercial 4.0 International), as 
). After six months, it is available underhttp://genome.cshlp.org/site/misc/terms.xhtml
first six months after the full-issue publication date (see 
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the
Service
Email Alerting
  
 click here.top right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the
 http://genome.cshlp.org/subscriptions
go to: Genome Research To subscribe to 
© 2020 Freeman et al.; Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on August 12, 2020 - Published by genome.cshlp.orgDownloaded from 
